Press Releases | CereSpir Inc.

NEWS & PUBLICATIONS

Contents:

Press Releases

Cerespir Incorporated Secures Exclusive Worldwide Development and Commercialization Rights for CHF 5074 from Chiesi Farmaceutici S.p.A.

by Daniel Gray | Nov 8, 2013 | Press Release | 0 Comments

November 8, 2013 – New York, NY, and Parma, Italy – CereSpir™ Incorporated and Chiesi Farmaceutici S.p.A. today announced CereSpir has acquired the worldwide development and commercialization rights to CHF 5074, a novel, first-in-class small molecule microglia... read more

Cerespir Incorporated is Pleased with Positive Interim Phase 2 Results for CHF 5074 in Patients with Mild Cognitive Impairment, Presented by Chiesi at the AAIC 2013 Meeting in Boston

by Daniel Gray | Jul 26, 2013 | Press Release | 0 Comments

Patients with Mild Cognitive Impairment treated with CHF 5074 for up to 90 weeks demonstrated highly statistically significant improvements in verbal memory and executive function CHF 5074 is a first-in-class small molecule microglia modulator, the only compound of... read more

Cerespir Incorporated Announces Letter of Intent with Chiesi Farmaceutici SpA, to License Worldwide Development and Commercialization Rights for CHF 5074 to Cerespir

by Daniel Gray | Jul 26, 2013 | Press Release | 0 Comments

CHF 5074 is a novel, first-in-class small molecule microglia modulator created by Chiesi Final results of a 14-week, double-blind, placebo-controlled Phase 2 study in 96 MCI patients and interim data from the 90-week open-label extension study indicate CHF 5074... read more

Next Entries »